<code id='E667AF5176'></code><style id='E667AF5176'></style>
    • <acronym id='E667AF5176'></acronym>
      <center id='E667AF5176'><center id='E667AF5176'><tfoot id='E667AF5176'></tfoot></center><abbr id='E667AF5176'><dir id='E667AF5176'><tfoot id='E667AF5176'></tfoot><noframes id='E667AF5176'>

    • <optgroup id='E667AF5176'><strike id='E667AF5176'><sup id='E667AF5176'></sup></strike><code id='E667AF5176'></code></optgroup>
        1. <b id='E667AF5176'><label id='E667AF5176'><select id='E667AF5176'><dt id='E667AF5176'><span id='E667AF5176'></span></dt></select></label></b><u id='E667AF5176'></u>
          <i id='E667AF5176'><strike id='E667AF5176'><tt id='E667AF5176'><pre id='E667AF5176'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:comprehensive    Page View:29
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In